Navigation Links
Novel biomarkers in heart failure
Date:5/30/2009

Several new biomarkers have been recently described in Heart Failure (HF) syndrome either in stable chronic patients as in the settings of acute decompensation. Biomarkers are used to diagnose disease risk, to predict outcome and to tailor treatment to individuals.

Speaking at a press conference at Heart Failure 2009 in Nice, France, Prof Piotr Ponikowski, spokesperson for the European Society of Cardiology, presented these new findings, namely:

  • ST2 - a member of the interleukin (IL)-1 receptor family, markedly upregulated on the application of mechanical strain to cardiac myocytes; reported to be elevated in severe chronic HF, where independently predicts poor outcome; serial monitoring in acute decompensated HF may be useful for risk stratification
  • ultrasensitive troponins reflecting damage/loss of cardiomyocytes; elevation in chronic HF identifies poor outcome
  • advanced glycation end-products (AGEs) - molecules formed during a non-enzymatic reaction between proteins and sugar residues; there is an evidence that AGEs are related to the development and progression of HF in diabetic and non-diabetic patients;
  • adrenomedullin hormone which is a potent vasodilator, with inotropic and natriuretic properties; assessment of mid-regional part of the proadrenomedullin (MR-proADM test) has been proved to add additional information on standard of care in the diagnosis of acute HF and to be useful in prognostic evaluation of these patients
  • estrogens it has been recently shown that both low and high concentrations of circulating estradiol are powerful predictors of a poor prognosis in men with chronic HF; subjects with either reduced or increased concentrations of serum E2 have different clinical characteristics, suggesting that the underlying pathophysiological mechanisms are not the same

"Biomarker" is a very broad term that refers to parameter reflecting or characterizing a certain biological proce
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline
2. Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research
3. A novel marker of colorectal carcinoma
4. Novel approach estimates nanoparticles in environment
5. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
8. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
9. Novel therapy may prove effective in treatment of 30 percent of cancers
10. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a leading ... to present at the Jefferies 3rd Annual Healthcare Conference in New ... 2009. , , The presentations will be available to ... accessed by visiting http://investors.gentiva.com/events.cfm . Visitors ...
... ... New hope for a much needed new approach for tackling Alzheimer,s disease ... in Philadelphia. At the inaugural Targeting Alzheimer,s with Novel Therapeutics conference, ... Edward Tobinick MD, Director of the Institute for Neurological Research, a private ...
... Men Fly off the Shelves for Father,s Day , , ... for chronic lower back pain may lie in a $59.99 biomechanically-engineered ... be the turning point for the sixty million adults who reported ... shoe many claim to be a medical breakthrough is now available ...
... Inc. a technology and services company focused on global eClinical solutions ... 45th DIA Annual Meeting to be held later this month in ... well as a number of exciting new features and functionality in ... , Reaffirming our ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
... Over Half a Million Varicose Vein Patients Treated with VNUS Closure ... VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide ... venous reflux disease , the underlying cause of ... week, it estimates the number of patients treated with the VNUS ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 2Health News:New Immune Approach for Treatment of Alzheimer's Disease 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 4Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 3Health News:DATATRAK Announces New Products and Features at DIA San Diego 4Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:A Milestone of Opportunity for VNUS Medical Technologies 2Health News:A Milestone of Opportunity for VNUS Medical Technologies 3
(Date:12/22/2014)... DIEGO , Dec. 22, 2014  Pfenex Inc. ... Pfenex,s recombinant anthrax vaccine, has been filed and is ... funding provided by the Department of Health and Human ... Authority (BARDA). "We are extremely pleased to ... vaccine, Px563L.  This represents a significant milestone in our ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... , December 19, 2014 TODAY, ... in the World announced the appointment of Peter ... Vonsée, as Chief Channels and Partner Officer. ... 2004 through to its acquisition by Oracle in 2011. ... at Geneva and subsequently Convergys, ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
Bravo Vacuum Pump. Complete with tubing....
Stand with buffer tubes for calibration of Bravo pH capsule....
... lower esophhageal sphincter (LES) can ... a separate manometry system. pH ... identification accessory kit and Digitrapper ... locate the LES. The kit ...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
Medicine Products: